Case Study 1 — Four-Thirty in the Morning: The Troponin That Lied

A clinical case. Walt Prosser is an illustrative composite; the biotin–troponin interference, the FDA safety communications, and the assay mechanics are not.

Setup

04:32. Walt Prosser, 68, wakes with chest pressure and an ache down the inside of his left arm.

04:51. His neighbour, Ray, drives him to the emergency department. On the way out, Ray sweeps the contents of the kitchen counter into a carrier bag — three prescription bottles and nine supplement bottles — because his late wife had been ill for a long time and he had learned to do that.

That decision is the entire case study.

05:20. Triage. History: chest pressure, radiating, 45 minutes, now easing. Type 2 diabetes eleven years, on metformin. Statin. ACE inhibitor. Ex-smoker, quit 1998. Father died of a myocardial infarction at 71.

A textbook pre-test probability.

05:35. ECG — non-diagnostic. Some non-specific changes, nothing that meets criteria.

05:48. Bloods, including troponin.

06:40. Troponin: low.

What that result means, and what it nearly did

Troponin is the protein released when cardiac muscle is damaged. In a patient with chest pain and a non-diagnostic ECG, it is the single most important determinant of what happens next.

Low troponin plus a non-diagnostic ECG plus settling symptoms is a reassuring combination. It moves the working impression away from acute coronary syndrome, and depending on local protocol it points toward a period of observation with a repeat, or toward discharge with outpatient follow-up.

The working impression started moving toward musculoskeletal or reflux-related chest pain.

Walt was, at that point, a man having a cardiac event whose blood test said he wasn't.

The bag

07:15. A junior doctor — early in her rotation, and taught by someone who insisted on it — went through the carrier bag properly, writing each item down rather than noting "takes vitamins."

Bottle seven was an "Advanced Immune Support Complex."

She read the panel. Among the ingredients: biotin, 3,000 micrograms.

That is roughly a hundred times the adequate intake. It is a completely ordinary dose for a supplement, because biotin is marketed for hair, skin and nails and gets added to a great many formulations at doses far above any nutritional requirement.

She had heard of biotin interference. Most people haven't.

The mechanism

Many immunoassays — including several widely used troponin assays — rely on the biotin–streptavidin binding system.

Streptavidin binds biotin with extraordinary affinity, and that binding is used as the molecular "velcro" that anchors antibodies and captures the target molecule within the assay.

Now flood the sample with free biotin from a supplement.

The free biotin competes with the assay's own biotinylated components for streptavidin binding sites. The system is saturated by biotin that isn't attached to anything the test is trying to measure.

And the direction of the resulting error depends on the assay's architecture:

Troponin assays are commonly sandwich format. Which means the error runs toward false reassurance — the worst possible direction for a test whose job is to catch a heart attack.

⚠️ The FDA issued a safety communication on this in 2017, updated in 2019. It advised patients to tell clinicians about biotin and advised clinicians to consider interference when results don't fit the clinical picture. It reported a death associated with a falsely low troponin result in a patient taking high-dose biotin.

What happened next

07:40. She raised it. The registrar agreed it was worth excluding.

08:05. Troponin repeated on a different analytical platform — one using a different capture chemistry, not biotin-dependent.

09:20. Elevated.

09:35. Cardiology referral. Admitted. Investigated and managed appropriately.

He did well.

The four things that had to go right

This is why it's a case study rather than a note, because Walt's outcome depended on a chain of contingencies, none of which was systemic.

1. Ray took the bottles. Not a list, not a memory — the physical containers, with labels, into the room where decisions were being made. He did this because of an unrelated prior experience.

2. The junior doctor went through them individually. "Takes vitamins" would have been an accurate and useless entry.

3. She had heard of biotin interference. This is not universally taught, and the FDA communication is seven years old and not widely known outside laboratory medicine.

4. The department had access to a second platform. Not everywhere does.

Remove any one and the story ends differently.

💡 Aha moment. Notice what makes this failure mode categorically different from everything else in Part III.

The biotin did nothing to Walt's body. It didn't damage his heart, interact with his metformin, or exceed a toxicity threshold. It is, pharmacologically, inert at that dose.

It attacked the measurement.

Every other harm in this book operates on the patient. This one operates on the information the clinicians are using to decide what to do about the patient — which is a route to harm that no amount of physiological safety testing would ever detect, and which the phrase "can't hurt" is completely unequipped to anticipate.

You cannot be careful about a risk you have no category for.

Why nobody knew

Walt didn't know, because he bought an immune supplement and biotin was one of eleven ingredients on a panel he had never read.

His GP didn't know, because supplements weren't on his record — they never are.

His pharmacist didn't know, because he bought it in a supermarket.

His family didn't know it mattered, because "vitamins" is a category that means harmless to almost everyone.

And the manufacturer had done nothing wrong. Biotin at 3,000 µg is legal, common, and — under DSHEA (§16.1) — requires no pre-market assessment of anything, including whether it might make a cardiac blood test read low.

There is no villain in this story, which is exactly the problem. It is a systems failure with eleven ingredients and no author — Chapter 1's pipeline, arriving in an emergency department.

What changed for Walt

And he told Ray, who now has his own list.

Analysis

1. The harm was to the measurement, not the patient. ⚠️ This category barely exists in public understanding and it is not covered by any intuition about supplement safety. "Can't hurt" cannot anticipate it.

2. The error ran toward false reassurance. Sandwich assays go low. Of all the directions an error could take on a troponin, that is the worst one.

3. Every safeguard was a person, not a system. Ray's habit. The junior doctor's teacher. Her memory. The department's second platform. Four coincidences, no protocol.

4. Nobody did anything wrong. The manufacturer complied with DSHEA. The first clinicians interpreted a low troponin correctly given the information they had. The information was wrong, and nothing in the system was designed to surface why.

5. And the fix is absurdly cheap. ⚠️ A list. In a phone. Four minutes. Or — better, given that this scenario often involves someone who can't speak for themselves — a card in a wallet. This book has asked three times because it is the highest expected-value action in Part III and it costs nothing.

Discussion Questions

1. Four things had to go right, none of them systemic. Design the system change that would make this robust. Consider: mandatory supplement fields in records, pharmacy integration, assay redesign, point-of-sale warnings. What does each cost, and who resists it?

2. Biotin is legal at 3,000 µg, requires no pre-market assessment, and can invalidate a cardiac blood test. Is that an acceptable regulatory outcome? What would you change, and what would you lose?

3. "Takes vitamins" is a common and useless record entry. How would you get clinicians to itemize? Is this a training problem, a time problem, or a record-design problem?

4. The chapter says "you cannot be careful about a risk you have no category for." Name two other risks in this book that fall into that description.

5. Walt's outcome hinged on a junior doctor's memory of an FDA communication issued seven years earlier. How should safety information like this reach front-line clinicians? Why doesn't it?

Your Turn

Two things. The first takes thirty seconds.

1. ⚠️ Check whether you take biotin. Look at every supplement you own — particularly "hair, skin and nails," "immune" blends, and B-complexes. Biotin appears in all three at doses hundreds of times the adequate intake, and almost nobody knows it's there.

If you find it: you don't necessarily need to stop. You need to tell a clinician before any blood test, and stop it several days beforehand for planned tests.

2. ⚠️ Write the list. Every supplement and medication, with doses.

• In your phone — a note called Medications, or your phone's medical ID (accessible from a locked screen, which is the entire point)
• On a card in your wallet — because phones lock, run out of battery, and are useless if you can't unlock them
• And tell one other person it exists. A partner. A neighbour. An adult child.

That last instruction is the one people skip and it's the one that mattered here. Ray grabbed the bottles because of something that happened to him years earlier. He shouldn't have needed to.

Four minutes. This is the last time this book asks.